Trinity Biotech PLC filed a Post-Effective Amendment No. 1 to its F-1 Registration Statement, registering up to 33,752,429 American Depositary Shares (ADSs) for resale by YA II PN, LTD., the Selling Securityholder. This action is pursuant to a Standby Equity Purchase Agreement allowing the company to sell up to $25 million in ADSs to the investor. While Trinity Biotech will not receive proceeds from the Selling Securityholder's resale, it may receive up to $25 million from direct sales to the investor, intended for operating expenses, working capital, and general corporate purposes. The filing also updates information to reflect fiscal year ended December 31, 2025 results and a recent debt amendment.